Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1073 articles by Jacob Bell
-
Bellus shares plummet as cough drug fails Phase 2 test
July 6, 2020 -
Amgen prevails in high-stakes drug case against Novartis
July 1, 2020 -
Gilead pricing suggests it will make a business out of COVID-19 drug
June 30, 2020 -
Intercept's NASH drug faces its biggest delay yet
June 29, 2020 -
FDA rejects AbbVie's eye drug, citing safety concerns
June 26, 2020 -
Sanofi's fight for a better research reputation
June 23, 2020 -
Sarepta tries to fine-tune its gene therapy approach
June 22, 2020 -
In big year for microbiome drugs, a small biotech sets the bar
June 19, 2020 -
Sanofi's latest investment signals long-term focus on vaccines
June 16, 2020 -
Neurocrine bets $2B on Takeda's psychiatry drugs
June 16, 2020 -
Magenta's technology attracts another gene therapy developer
June 15, 2020 -
Agios, seeking a new strategy, touts positive data and marketing deal
June 12, 2020 -
Lundbeck to cut more than 100 jobs as it remodels R&D
June 9, 2020 -
Amid a pandemic, Atlas becomes latest venture firm to raise cash for drug startups
June 5, 2020 -
Pfizer business head details new $500M project for investing in public biotechs
June 3, 2020 -
Details lacking, but new remdesivir data point to a benefit for 'moderate' COVID-19 patients
June 1, 2020 -
Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'
May 29, 2020 -
Contaminated diabetes drugs raise red flag for FDA oversight
May 28, 2020 -
Venture capital found its footing in biotech. Then came the virus.
May 26, 2020 -
High expectations cast a shadow over Gilead and Galapagos' positive data
May 21, 2020 -
Little-known drug manufacturer gets big contract for COVID-19 response
May 19, 2020 -
Gilead licenses COVID-19 drug to 5 generics companies
May 13, 2020 -
GenFit delivers latest NASH drug failure
May 11, 2020 -
MyoKardia pops as heart drug passes most important test
May 11, 2020 -
After trial failure, Enanta narrows its focus to NASH
May 7, 2020